| Background: Malignant tumor is a kind of common disease which does severe harm for people' health. To the present, the main methods of curing tumor are surgery, radiation and chemotherapy. Among them, chemotherapy is a method that can't be taken place of because only it emphasizes to cure the whole body. However a lot of clinical practice and laboratory researches showed that the patients with the same clinical stage and the same pathological pattern had different prognosis following the same treatment; other way, the sensitivity of the tumor cells to drugs might change with the progression of chemotherapy. So individual chemotherapy, which means that doctors select different drugs to individuals, is emphasized. Although it is a good way to use cancer cells to select sensitive drugs for individual chemotherapy, it is difficult to get the fresh tumor tissue for some reasons in our country. Therefore, the key of individual chemotherapy is to find a new specimen which is easy to get and capable of substituting for tumor tissue.Human genome project demonstrated that there are same genomes in the same individuals, and the genomes of the cancer cells would be the same as those of the other cells. Although protein expression and function of the different tissues and cells at the different condition were different, the different cells of the same individual should possess the same potentialities when they met the same attacks. So we speculate body cells and tumor cells of the same individual should have the same reaction to drugs. It is possible for us to use lymphocytes to take place of cancer cells in selecting sensitive anticancer drugs when cancer cells couldn't be gotten.Objective: Our study attempted to clarify whether or not lymphocytes may take place of cancer cells to select the sensitive drugs by comparing difference and correlation between cancer cells and lymphocytes in the same patient to anticancerdrugs in inhibition rates.Method: The inhibiting rates of 8 kinds of anticancer drugs, Epirubicin (e-ADM), Methotrexate (MIX), Vincristine (VCR), Fluorouracil (5-Fu), Cisplatin (DDP), Carboplatin (CP), Cyclophosphamide (CTX) and Etoposide (Vp-16) to the cancer cells of the breast carcinoma cultured in vitro in 13 patients and those of 10 kinds of anticancer drugs, e-ADM, MIX, Nonvincaleukoblastine (NVB), VCR, 5-Fu, Teniposide (VM-16), DDP, CP, CTX and Vp-16 to the cancer cells of colorectal carcinoma cultured in vitro in 9 patients were measured by MTT method to observe the difference of inhibiting rates of anticancer drugs to the cancer cells of the different individual with the same pattern. The inhibiting rates of 10 kinds of anticancer drugs, e-ADM, MTX, NVB, VCR, 5-Fu, VM-16, DDP, CP, CTX and Vp-16 to cancer cells and peripheral blood lymphocytes of 27 tumor patients were measured by MTT method and the difference and correlation of inhibition rates of anticancer drugs to cancer cells and lymphocytes of the same patient were analyzed.Results (1) The average inhibiting rates of e-ADM, MTX, VCR, 5-Fu, DDP, CP., CTX and Vp-16 to breast carcinoma cells were 31.1538%, 32.7692%, 46.4165%, 34.1538%, 46.3846%, 52.6154%, 54.4615%, 40.2308% and 42.6154% respectively; the outstanding sensitive rates were 7.7% (1/13), 23.1% (3/13), 38.5% (5/13), 7.7% (1/13), 38.5% (5/13), 53.8% (7/13), 69.2% (9/13), 38.5% (5/13) and 38.5% (5/13)) respectively, the sensitive rates were 38.5% (5/13), 30.8% (4/13), 38.5% (5/13), 61.5% (8/13), 61.5% (8/13), 23.1% (3/13), 7.7% (1/13), 15.4% (2/13) and 30.8% (4/13) respectively, the resistant rates were 53.8% (7/13), 46.2% (6/13), 23.1% (3/13), 30.8% (4/13), 0% (0/13), 23.1% (7/13), 23.1% (3/13), 23.1% (3/13) and 30.8% (4/13) respectively; the standard deviations of the inhibiting rates were 13.6405%, 13.4608%, 24.0299%, 12.0613%, 12.5136%, 25.2868%, 20.5694%, 26.3298% and 21.6632% respectively; the ranges of the inhibiting rates were 50, 39, 85,42, 33, 90,63, 84 and 80 respectively. The average inhibiting rates of e-ADM, MTX, NVB, VCR, 5-Fu, VM-16, DDP, CP., CTX and Vp-16 to... |
PDF Full Text Request